期刊
MOLECULAR CELL
卷 81, 期 17, 页码 3481-+出版社
CELL PRESS
DOI: 10.1016/j.molcel.2021.07.019
关键词
-
资金
- Genetic Perturbation Platform
- Proteomics Platform
- Center for the Development of Therapeutics
- Cancer Program
- Deerfield-Broad Discovery Research Collaboration [F32 CA232543-01, 1R01CA233626-01A1]
PRMT5 functions as an essential arginine methyltransferase using modular adaptor proteins with a common binding motif for substrate recruitment. Disruption of the PRMT5-substrate adaptor interface impairs the growth of MTAP-null tumor cells, making it a potential target for therapeutic inhibitors of PRMT5.
PRMT5 is an essential arginine methyltransferase and a therapeutic target in MTAP-null cancers. PRMT5 uses adaptor proteins for substrate recruitment through a previously undefined mechanism. Here, we identify an evolutionarily conserved peptide sequence shared among the three known substrate adaptors (CLNS1A, RIOK1, and COPR5) and show that it is necessary and sufficient for interaction with PRMT5. We demonstrate that PRMT5 uses modular adaptor proteins containing a common binding motif for substrate recruitment, comparable with other enzyme classes such as kinases and E3 ligases. We structurally resolve the interface with PRMT5 and show via genetic perturbation that it is required for methylation of adaptor-recruited substrates including the spliceosome, histones, and ribosomal complexes. Furthermore, disruption of this site affects Sm spliceosome activity, leading to intron retention. Genetic disruption of the PRMT5-substrate adaptor interface impairs growth of MTAP-null tumor cells and is thus a site for development of therapeutic inhibitors of PRMT5.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据